Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2022
Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial.
Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06310902 (Single-cell Sequencing Analysis of Resectable/Borderline Resectable Pancreatic Cancer Patients), which is not on this map. Cited by 403 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Single-cell Sequencing Analysis of Resectable/Borderline Resectable Pancreatic Cancer Patients
Who cites it
403 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Neoadjuvant Treatment Versus Upfront Surgery for Resectable Pancreatic Ductal Adenocarcinoma-A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Medicina (Kaunas, Lithuania) · 2026Pooled it
- Neoadjuvant Therapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: A Systemic Review and Meta-Analysis.The Journal of surgical research · 2025Pooled it
- Neoadjuvant treatment versus upfront surgery in borderline resectable and resectable pancreatic ductal adenocarcinoma: meta-analysis.BJS open · 2025Pooled it
- Mesenteric Versus Conventional Approach During Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma (MAPLE-PD trial): A Multicenter Randomized Controlled Trial.Annals of surgery · 2026Trial
- Perioperative therapy for resectable and borderline resectable pancreatic adenocarcinoma: an Academic Gastrointestinal Cancer Consortium Study.The oncologist · 2025Trial
- Postoperative Adverse Events Following Neoadjuvant Therapy and Surgery for Borderline Resectable Pancreatic Cancer in a Phase 2 Clinical Trial (Alliance A021501).Annals of surgical oncology · 2024Trial
- 11.5-Fr Large-Bore Plastic Stents Versus Fully Covered Self-Expandable Metallic Stents for the Management of Preoperative Endoscopic Biliary Obstruction in Pancreatic Cancer: A Multicenter Retrospective Cohort Study.Digestive diseases and sciences · 2026Article
- Predictive Factors for Occult Metastases in Clinically M0 Pancreatic Cancer: A Prospective Multicenter Analysis of Staging Laparoscopy.Annals of surgical oncology · 2026Article
- Clinical Efficacy of Tislelizumab Plus Gemcitabine-Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer and Chemoresistance Analysis: A Prospective Pilot Study.Annals of surgical oncology · 2026Article
- Neoadjuvant Early Stereotactic Body Radiation Therapy Followed by Chemoimmunotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer.Advances in radiation oncology · 2026Article
- Editorial for PREOPANC-2, a multicenter, open-label, phase 3 randomized trial comparing neoadjuvant FOLFIRINOXHepatobiliary surgery and nutrition · 2026Article
- Do Postoperative Complications Impact Adjuvant Chemotherapy in Patients Undergoing Left-Side Pancreatectomy for Pancreatic Cancer?Annals of surgical oncology · 2026Article
- Standardizing computed tomographic assessment of the mesopancreas in pancreatic cancer patients.Abdominal radiology (New York) · 2026Article
- Global Perspectives on Radiotherapy Utilization for Pancreatic Ductal Adenocarcinoma.Journal of gastrointestinal cancer · 2026Article
- Extrapancreatic extension exhibits tumor size-dependent prognostic impact in pancreatic cancer.Scientific reports · 2026Article
- Challenges and opportunities in combining radiotherapy and immunotherapy for localized pancreatic cancer.Nature reviews. Gastroenterology & hepatology · 2026Review
- Current practices and challenges in the management of nonmetastatic pancreatic adenocarcinoma: results of an EORTC survey.ESMO gastrointestinal oncology · 2026Article
- CT-based Node-RADS for evaluating regional lymph node metastasis and postoperative recurrence in patients with pancreatic ductal adenocarcinoma undergoing upfront surgery.European radiology · 2026Article
- Article
- Transcriptome-Based Classification of Resected Pancreatic Ductal Adenocarcinoma Enhances Prognostic Modelling Accuracy of Overall Survival Following Adjuvant Treatment.International journal of cancer · 2026Article
343 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
Authors and funding
33 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe benefit of neoadjuvant chemoradiotherapy in resectable and borderline resectable pancreatic cancer remains controversial. Initial results of the PREOPANC trial failed to demonstrate a statistically significant overall survival (OS) benefit. The long-term results are reported.
methodsIn this multicenter, phase III trial, patients with resectable and borderline resectable pancreatic cancer were randomly assigned (1:1) to neoadjuvant chemoradiotherapy or upfront surgery in 16 Dutch centers. Neoadjuvant chemoradiotherapy consisted of three cycles of gemcitabine combined with 36 Gy radiotherapy in 15 fractions during the second cycle. After restaging, patients underwent surgery followed by four cycles of adjuvant gemcitabine. Patients in the upfront surgery group underwent surgery followed by six cycles of adjuvant gemcitabine. The primary outcome was OS by intention-to-treat. No safety data were collected beyond the initial report of the trial.
resultsBetween April 24, 2013, and July 25, 2017, 246 eligible patients were randomly assigned to neoadjuvant chemoradiotherapy (n = 119) and upfront surgery (n = 127). At a median follow-up of 59 months, the OS was better in the neoadjuvant chemoradiotherapy group than in the upfront surgery group (hazard ratio, 0.73; 95% CI, 0.56 to 0.96;
conclusionNeoadjuvant gemcitabine-based chemoradiotherapy followed by surgery and adjuvant gemcitabine improves OS compared with upfront surgery and adjuvant gemcitabine in resectable and borderline resectable pancreatic cancer.
Indexed as
Identifiers
35084987What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.